Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pulmonary Hypertension
Pharma
Unapproved in US for decades, levosimendan stumbles in ph. 3
Despite the flop, Tenax has zeroed in on a prespecified subgroup of patients with greater disease burden and plans to request a meeting with the FDA.
Angus Liu
Aug 10, 2026 4:40pm
Merck releases results from successful trial of Winrevair
Sep 30, 2025 8:00am
Merck's Winrevair cuts death, morbidity risk by 76%
Mar 31, 2025 10:00am
Ferrer calls out shortcomings of pulmonary hypertension pathways
Nov 20, 2024 2:15pm
FDA signs off on Merck’s potential blockbuster Winrevair for PAH
Mar 26, 2024 5:11pm
J&J dumps Opsumit trial upon pulmonary hypertension flop
Sep 7, 2023 11:03am
